Non-Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Evaluation of Anthropometric Measurements and Biochemical Parameters in Non-Alcoholic Fatty Liver Patients and Healthy Individuals
| NCT number | NCT05810506 |
| Other study ID # | Tuba ONAY |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | October 1, 2021 |
| Est. completion date | March 17, 2023 |
| Verified date | April 2023 |
| Source | Bandirma Onyedi Eylül University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
The aim of this study; Which anthropometric measurement and ratio (BMI, waist circumference, hip circumference, waist-to-hip ratio, neck circumference, waist-height ratio, body shape index, body roundness index, visceral adiposity index) is a better indicator in healthy individuals with NAFLD and their biochemical parameters is to evaluate.
| Status | Completed |
| Enrollment | 82 |
| Est. completion date | March 17, 2023 |
| Est. primary completion date | April 30, 2022 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 30 Years to 64 Years |
| Eligibility | Inclusion Criteria for NAFLD patients: - should sign a voluntary consent form - do not consume alcohol - be between 30-64 years old - have been diagnosed with NAFLD by applying to the gastroenterology outpatient clinic - have no other diseases - should not use medication Inclusion Criteria for healthy individuals: - should sign a voluntary consent form - do not consume alcohol - be between 30-64 years old - not have any acute or chronic diseases Exclusion Criteria for NAFLD patients: - consuming alcohol - not be between 30-64 years old - being pregnant or lactating - any surgery in the last 3 months - Not being diagnosed with NAFLD - Hepatitis B-C, Wilson's disease, autoimmune liver diseases, cancer, cirrhosis, inflammatory bowel diseases, celiac, diabetes, cystic fibrosis, hereditary diseases, irritable bowel syndrome, kidney diseases, AIDS-HIV etc. have a disease - using any medication other than fatty liver Exclusion Criteria for healthy individuals: - consuming alcohol - any acute or chronic illness - being pregnant-lactating - using any medicine - not be between 30-64 years old |
| Country | Name | City | State |
|---|---|---|---|
| Turkey | Bandirma onyedi eylül university | Bandirma | Balikesir |
| Lead Sponsor | Collaborator |
|---|---|
| Bandirma Onyedi Eylül University |
Turkey,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Body weight | Body weight measurements of the patients will be made by removing thick clothes and shoes, and by means of TANITA BC-418 MA brand Bioelectrical Impedance Analysis (BIA). | Six month | |
| Primary | Height | The height of the patients will be measured with a stadiometer while the feet are together and the head is in the Frankford plane. | Six month | |
| Primary | Body fat percentage | The body fat mass of individuals will be measured with the TANITA BC-418 MA BIA analyzer. | Six month | |
| Primary | Neck circumference | Measure with a non-stretchable tape measure horizontally at the upper edge of the laryngeal prominence with the head upright and eyes facing forward. | Six month | |
| Primary | Waist circumference | The patient's side will be passed to the side of the patient and the circumference passing through the middle point will be measured between the lowest point of the rib bone and the iliac crest. | Six month | |
| Primary | Hip circumference | The largest circumference between the waist and knees will be measured by going to the side of the patient. | Six month | |
| Primary | Body mass index | It will be calculated by dividing the body weight by the square of the height | Six month | |
| Primary | Waist-to-length ratio | It is the ratio of waist circumference to height. | Six month | |
| Primary | Waist to hip ratio | It is the ratio of waist circumference to hip circumference. | Six month | |
| Primary | Body shape index | Body shape index of patients; with height, waist circumference and BMI values; It will be calculated using the formula [Waist circumference/ (BKI )2/3* Height 1/2]. | Six month | |
| Primary | Body roundness index | The body roundness index of the patients will be calculated using the formula [364.2-365.5xv1-[(waist circumference/(2p))2/(0.5 x height)2]. | Six month | |
| Primary | Visceral adiposity index | Patients' visceral adiposity index for men: [Waist circumference/ 39.68 + (1.88 × [BMI])] × [(TG)/1.03] × (1.31/HDL); for women: will be calculated using the formulas [Waist circumference /36.58 + (1.89 × BMI)] × (TG/0.81) × (1.52/HDL). | Six month |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
| Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
| Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
| Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
| Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
| Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
| Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
| Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
| Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
| Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
| Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
| Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
| Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
| Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
| Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
| Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
| Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
| Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
| Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |